Regeneron COVID-19 Cocktail’s Flame To Burn Brightly But Unclear For How Long
Antibody Products Will Be An Important Option Until Vaccines Reduce Infections
Executive Summary
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.
You may also be interested in...
Coronavirus Update: Regeneron's REGEN-COV Authorized For Prevention
Regeneron's antibody cocktail gets emergency authorization for post-exposure prophylaxis from the US FDA. Daewoong's camostat shows efficacy in older patients in South Korean trial.
#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
EMA Reviewing Two MAb Combinations For COVID-19
The European Medicines Agency's special review process that was used to help EU member states issue emergency use approvals for dexamethasone in COVID-19 patients is now being applied to two antibody combinations from Regeneron/Roche and Lilly.